Endonovo Therapeutics, Inc.
ENDV · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $2 | $3 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $7 | $7 | $7 | $7 |
| Enterprise Value | $7 | $9 | $10 | $8 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -92.8% | 3.6% | 85.2% | – |
| Gross Profit | -$1 | -$1 | $0 | $0 |
| % Margin | -6,125.6% | -366.9% | 92.6% | 79.5% |
| EBITDA | -$1 | $9 | -$17 | -$2 |
| % Margin | -9,373.7% | 6,313.2% | -12,194.9% | -2,072.1% |
| Net Income | -$3 | $7 | -$18 | -$3 |
| % Margin | -27,853.2% | 4,937.6% | -13,649.2% | -4,247.2% |
| EPS Diluted | -0.005 | 0.005 | -0.13 | -0.052 |
| % Growth | -200% | 103.9% | -150.5% | – |
| Operating Cash Flow | $0 | $0 | -$1 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | $0 | -$1 | -$1 |